4.2 Article

Assessing anxious features in depressed outpatients

出版社

WILEY
DOI: 10.1002/mpr.353

关键词

depression; anxiety; rating scales; STAR(star)D; measurement-based care

资金

  1. National Institute of Mental Health (NIMH) [N01MH90003]
  2. National Institutes of Health (NIH)
  3. National Alliance for Research on Schizophrenia and Depression (NARSAD)
  4. Abbott Laboratories
  5. Alkermes
  6. Lichtwer Pharma GmbH
  7. Lorex Pharmaceuticals
  8. Aspect Medical Systems
  9. Astra-Zeneca
  10. Bristol-Myers Squibb Company
  11. Cephalon
  12. Cyberonics
  13. Eli Lilly Company
  14. Forest Pharmaceuticals Inc.
  15. GlaxoSmithkline
  16. J & J Pharmaceuticals
  17. Novartis
  18. Organon Inc.
  19. PamLab
  20. LLC
  21. Pfizer Inc
  22. Pharmavite
  23. Roche
  24. Sanofi/Synthelabo
  25. Solvay Pharmaceuticals, Inc.
  26. Wyeth-Ayerst Laboratories
  27. National Institute of Mental Health
  28. Stanley Medical Research Institute
  29. Cyberonics, Inc.
  30. Neuronetics, Inc.
  31. Magstim
  32. Advanced Neuromodulation Systems
  33. Department of Health and Human Services
  34. Pfizer, Inc.
  35. Lilly, Inc.
  36. Forest Laboratories, Inc.
  37. GlaxoSmithKline, Inc.
  38. Mitsubishi-Tokyo
  39. Merck, Inc.
  40. Biovail Laboratories, Inc.
  41. Wyeth, Inc.
  42. Berlex Laboratories
  43. Novartis Pharmaceuticals, Inc.
  44. Sepracor, Inc.
  45. Boehringer-Ingelheim
  46. Sanofi-Synthelabo

向作者/读者索取更多资源

Both the 17-item Hamilton Rating Scale for Depression (HRSD17) and 30-item Inventory of Depressive Symptomatology - Clinician-rated (IDS-C-30) contain a subscale that assesses anxious symptoms. We used classical test theory and item response theory methods to assess and compare the psychometric properties of the two anxiety subscales (HRSDANX and IDS-C-ANX) in a large sample (N = 3453) of outpatients with non-psychotic major depressive disorder in the Sequenced Treatment Alternatives to Relieve Depression (STAR(star)D) study. Approximately 48% of evaluable participants had at least one concurrent anxiety disorder by the self-report Psychiatric Diagnostic Screening Questionnaire (PDSQ). The HRSDANX and IDS-C-ANX were highly correlated (r = 0.75) and both had moderate internal consistency given their limited number of items (HRSDANX Cronbach's alpha = 0.48; IDS-C-ANX Cronbach's alpha = 0.58). The optimal threshold for ascribing the presence/absence of anxious features was found at a total score of eight or nine for the HRSDANX and seven or eight for the IDS-C-ANX. It would seem beneficial to delete item 17 (loss of insight) from the HRSDANX as it negatively correlated with the scale's total score. Both the HRSDANX and IDS-C-ANX subscales have acceptable psychometric properties and can be used to identify anxious features for clinical or research purposes. Copyright (C) 2011 John Wiley & Sons, Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据